Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Genomics, IDT Partner on Small Synthetic Gene Products

NEW YORK (GenomeWeb News) – Synthetic Genomics and Integrated DNA Technologies today announced a deal to manufacture, market, and commercialize small synthetic gene products.

The deal, the terms of which were not disclosed, calls for the companies to construct custom, synthetic, double-stranded nucleic acids up to 5 kilobases. IDT will combine its expertise in custom oligonucleotide manufacturing with Synthetic Genomics' technology to assemble small gene constructs.

The collaboration is expected to result in "more affordable, efficient gene synthesis products that can be delivered more quickly to the synthetic biology community," Joe Walder, founder and CEO of IDT, said in a statement.

Craig Venter, founder and CEO of Synthetic Genomics, called the deal "a key component to advance our synthetic DNA business."

A few months ago Synthetic Genomics and Plenus announced the formation of a new company called Agradis to develop and commercialize products leveraging new genomics technologies.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.